Navigation Links
Pharmacyclics Announces Results of Registered Direct Offering
Date:6/17/2011

arbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011
2. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
3. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
4. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
5. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
6. Pharmacyclics, Inc. Rights Offering Oversubscribed
7. Pharmacyclics Announces Subscription Price for Rights Offering
8. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
9. Pharmacyclics Files Registration Statement for Rights Offering
10. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
(Date:12/19/2014)... 18, 2014 Ed Bilsky, Ph.D., vice ... Center for Excellence in the Neurosciences (CEN), and professor ... been selected as a member of the prestigious Dana ... neuroscientist from Maine to receive this honor. , ... entirely by the Dana Foundation. Its mission is ...
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... matrix for dry state room temperature transport and ... ... GenVault Corporation, the,leader in dry, room temperature biosample management, ... DNA is a,proprietary inorganic matrix with built-in oxidative protection and,antimicrobial ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... from October 13-14, 2008 at the Waldorf Astoria,in ... Officer, will,provide an overview of the company on ... About Pharmasset, Pharmasset is a clinical-stage pharmaceutical ...
... Colo., Oct. 8 GeneThera, Inc.,(Pink Sheets: GTHR), ... Chairman and CEO, Dr. Tony Milici, is featured ... The interview gives viewers an overview of ... press release., To view the clip ...
Cached Biology Technology:GenVault Corporation Launches GenTegra(TM) DNA 2GenVault Corporation Launches GenTegra(TM) DNA 3[video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.net's 3-Minute Press Show 2
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... at Brown University and Women & Infants Hospital have invented ... potentially powerful new means for conducting fertility research and could ... already used the lab-grown organ to mature human eggs. ... this is the first time that anyone has created a ...
... attack in a young athlete on the playing field is ... more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder ... young people but which affects people of all ages. So ... by Thomas L. Force, M.D., James C. Wilson Professor of ...
... D.C. (September 14, 2010) -- Piezoelectric materials have fantastic ... And vice-versa, they contract or expand when jolted with ... Greek word meaning to squeeze or press, the piezoelectric ... in several crystals in 1880. But in 1917, a ...
Cached Biology News:Researchers build 'artificial ovary' to develop oocytes into mature human eggs 2Researchers build 'artificial ovary' to develop oocytes into mature human eggs 3Researchers nationwide ask for new focus on 'sudden death' heart disorder 2Researchers nationwide ask for new focus on 'sudden death' heart disorder 3Lead-free piezoelectric materials of the future 2
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Tracker Datamatrix TRxD reads any 1D and 2D barcodes within 0.5 seconds....
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: